Golpimec (Fingolimod)

Golpimec is primarily indicated for the management of multiple sclerosis in adult patients. Its clinical use focuses on reducing relapse rates and slowing disease progression.

• Relapsing‑remitting multiple sclerosis (RRMS) in adults
• Reducing the frequency of clinical relapses
• Delaying accumulation of disability as measured by the Expanded Disability Status Scale
• Decreasing new or enlarging MRI lesions
• Used as part of a disease‑modifying therapy regimen under specialist supervision

Golpimec may cause a range of adverse effects, which are generally categorized by frequency and severity.

Common

• Headache (persistent)
• Fatigue (moderate)
• Diarrhea (mild to moderate)
• Upper respiratory tract infection (viral)
• Elevated liver enzymes (asymptomatic)
• Nausea (occasionally)

Serious

• Severe infections (herpes, opportunistic)
• Cardiac conduction abnormalities (bradycardia, AV block)
• Macular edema (visual disturbances)
• Respiratory depression (especially with concomitant CNS depressants)
• Significant lymphopenia (risk of infection)
• Liver injury (hepatitis, elevated transaminases)

When prescribing Golpimec, clinicians must consider several precautions to ensure patient safety and to minimize the risk of serious complications.

• Contraindicated in pregnancy (Category X) and requires effective contraception
• Baseline cardiac assessment is required due to risk of bradycardia
• Perform liver function tests before initiation and monitor periodically
• Screen for active infections, especially varicella‑zoster virus
• Monitor complete blood count for lymphocyte reductions
• Assess for macular edema with ophthalmologic examination at baseline and during therapy
• Avoid use in patients with severe uncontrolled asthma

Golpimec can interact with other medicines, affecting its efficacy or increasing safety risks. Interactions are grouped by the level of clinical concern.

Avoid

• Live vaccines (e.g., yellow fever, varicella) due to impaired immune response
• Strong CYP4F2 inhibitors that may increase fingolimod exposure
• Anticholinergic agents that could exacerbate cardiac effects

Use with caution

• Other immunosuppressants (e.g., azathioprine, methotrexate) increasing infection risk
• CYP3A4 inducers (e.g., rifampin) that may lower fingolimod levels
• CNS depressants (e.g., benzodiazepines) potentially enhancing respiratory depression
• Antihypertensive drugs that may compound bradycardia